News | February 23, 2023
Research underscores Beyfortus’ potential to prevent RSV disease in infants
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
There is a fast resurgence in the transplant activities post COVID
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023
The partnership is announced at Aero India 2023, Bangalore
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
Themis will market this drug with the brand name REMITHEM.
Subscribe To Our Newsletter & Stay Updated
